Phase III randomized, placebo-controlled, double-blind study of intravenous calcium and magnesium to prevent oxaliplatin-induced sensory neurotoxicity (N08CB/Alliance).
about
Chemotherapy-induced peripheral neuropathy: an update on the current understandingMolecular Biology and Clinical Mitigation of Cancer Treatment-Induced NeuropathyCalcium and Magnesium for Oxaliplatin-Induced Neurotoxicity: Issues in Study Design, Measurement, and AnalysisThe Use of Calcium and Magnesium to Prevent Neurotoxicity in Patients Receiving OxaliplatinChemotherapy-induced peripheral neurotoxicity and complementary and alternative medicines: progress and perspectiveCancer-treatment-induced neurotoxicity--focus on newer treatmentsOptimizing adjuvant therapy and survivorship care of stage III colon cancer.DocOx (AIO-PK0106): a phase II trial of docetaxel and oxaliplatin as a second line systemic therapy in patients with advanced pancreatic ductal adenocarcinoma.Comparison of oxaliplatin and paclitaxel-induced neuropathy (Alliance A151505).North Central Cancer Treatment Group/Alliance trial N08CA-the use of glutathione for prevention of paclitaxel/carboplatin-induced peripheral neuropathy: a phase 3 randomized, double-blind, placebo-controlled studyHerbal Medicine AC591 Prevents Oxaliplatin-Induced Peripheral Neuropathy in Animal Model and Cancer Patients.Efficacy of Drug Interventions for Chemotherapy-Induced Chronic Peripheral Neurotoxicity: A Network Meta-analysis[EXPRESS] Ion channels and neuronal hyperexcitability in chemotherapy-induced peripheral neuropathy; cause and effect?Predicting effects on oxaliplatin clearance: in vitro, kinetic and clinical studies of calcium- and magnesium-mediated oxaliplatin degradationMangafodipir a Selective Cytoprotectant - with Special Reference to Oxaliplatin and Its Association to Chemotherapy-Induced Peripheral Neuropathy (CIPN)Neuropathic symptoms, quality of life, and clinician perception of patient care in medical oncology outpatients with colorectal, breast, lung, and prostate cancer.Platinum-induced neurotoxicity and preventive strategies: past, present, and future[Chemotherapy-induced peripheral neuropathies: an integrative review of the literature].Neuropathic Symptoms and Their Risk Factors in Medical Oncology Outpatients With Colorectal vs. Breast, Lung, or Prostate Cancer: Results From a Prospective Multicenter Study.Initial safety report on the tolerability of modified FOLFOX6 as adjuvant therapy in patients with curatively resected stage II or III colon cancer (JFMC41-1001-C2: JOIN trial)The Globalization of Cooperative Groups.Clinical Course of Oxaliplatin-Induced Neuropathy: Results From the Randomized Phase III Trial N08CB (Alliance).New Insights into Potential Prevention and Management Options for Chemotherapy-Induced Peripheral Neuropathy.Genetic polymorphisms of SCN9A are associated with oxaliplatin-induced neuropathy.MC11C4: a pilot randomized, placebo-controlled, double-blind study of venlafaxine to prevent oxaliplatin-induced neuropathy.EXPRESS: Methylcobalamin ameliorates neuropathic pain induced by vincristine in rats: Effect on loss of peripheral nerve fibers and imbalance of cytokines in the spinal dorsal horn.Adjuvant FOLFOX treatment for stage III colon cancer: how many cycles are enough?National Cancer Institute-supported chemotherapy-induced peripheral neuropathy trials: outcomes and lessons.The search for treatments to reduce chemotherapy-induced peripheral neuropathy.Feasibility of sequential adjuvant chemotherapy with a 3-month oxaliplatin-based regimen followed by 3 months of capecitabine in patients with stage III and high-risk stage II colorectal cancer: JSWOG-C2 studyMagnetic field therapy in patients with cytostatics-induced polyneuropathy: A prospective randomized placebo-controlled phase-III studyCurrent use of drugs affecting the central nervous system for chemotherapy-induced peripheral neuropathy in cancer patients: a systematic review.Hypersensitivity reactions associated with oxaliplatin and their clinical management.Mechanism-based treatment for chemotherapy-induced peripheral neuropathic pain.The double-edged sword: Neurotoxicity of chemotherapy.Research design considerations for chronic pain prevention clinical trials: IMMPACT recommendations.Minimizing chemotherapy-induced peripheral neuropathy: preclinical and clinical development of new perspectives.Interim analysis of a phase II trial evaluating the safety and efficacy of capecitabine plus oxaliplatin (XELOX) as adjuvant therapy in Japanese patients with operated stage III colon cancer.Capecitabine, Oxaliplatin, and Bevacizumab (BCapOx) Regimen for Metastatic Colorectal Cancer.Factors associated with the development and severity of oxaliplatin-induced peripheral neuropathy: a systematic review.
P2860
Q26740689-1D3B79D4-0A49-4F32-9098-B4EED65B8D9FQ26747796-FE5D1DE6-B98D-4A36-B03F-1969500C20B4Q26777879-B091F8FA-4174-4B83-9973-F4F9CD7FFD5EQ26777881-22E58EBB-2B0A-4641-B252-743D689B223CQ26777967-42559A0A-1611-4658-96AB-B117EA1E2FDDQ26782604-8D293E5F-882B-400E-AA0E-14CDF0DF495CQ30249616-F58AD0E3-4408-4AF1-83A4-04855276C7B1Q30315797-9A4D976F-6A9A-4192-8306-D707C0393584Q33711444-735D4A90-2E99-4655-867C-0DC78B8E4068Q33717608-016E374F-3631-40DA-B26E-FBE625C5BFEDQ33770708-54945D93-F1CC-43D4-B843-08822B806B95Q33774892-C30C71EB-12CA-4D7F-8483-595850A56D1FQ33824948-A58BFC4B-E12B-4AD8-9BEA-E97E0E07064DQ33826355-D1B778FE-46C4-4731-8764-ACA09DC19220Q33868520-4E699751-0A80-4E04-86D9-1C87C6BF8023Q35002187-050307F0-6433-4863-A520-316C0F2B60D7Q35345734-0698D280-7923-4F87-AD2A-1932C39AFB1AQ35636254-0E214396-6C97-45C7-A552-61730105CF4CQ35778696-AF5EF0A3-B655-44D0-8431-6CC678FFABA9Q35799385-35C96291-1D53-44DC-A3E2-C3D56478C157Q36119749-62DC7555-B3F9-4531-BD2F-036D5AB18208Q36162504-2C22A92D-79E6-446B-A66E-15E33409B4DBQ36226275-B1EA643D-AA5B-4F99-9D31-86289D8D03EEQ36254372-5C7872AE-FAF2-4592-B632-67C4DE4ADF38Q37082272-6299B214-73AE-410A-9DD8-70A244BAFA41Q37114802-007118AD-6754-43D1-8671-AFD54AC6CC70Q37167151-3134A421-EAAD-410F-AD44-F5BF856BEA17Q37364316-EFBE025A-1A46-4A39-9D44-47F65F57E020Q37410650-9B656064-28AF-4A1B-ADB5-03E05BC888BAQ37446505-51C1483D-7B1B-44C3-AD96-7B9972B3B78CQ37595960-1FBAC061-3F06-4664-A3F0-4C1F253E2A7EQ38254351-DE50949F-518A-43F3-9E2C-3614BDC981D5Q38259295-C3F4ABED-C712-44AB-88BE-04264BC2CF4DQ38264622-C3FCE0F7-8116-4FD3-BEB5-038C3D3D3EA8Q38274890-076881F7-4A6D-492B-B813-217572DD49EFQ38426849-EC130B71-EA77-488C-87DD-56BE4B187436Q38522262-49EC4919-904B-4AFB-A319-EAC8A530CF87Q38616424-9F7917CB-7AF0-4819-84EF-9AF46F488A12Q38626963-B30F718F-F57C-49BF-A5D1-83E562C85D81Q38707400-E1EA28E1-6934-4173-B808-B2572D4F170C
P2860
Phase III randomized, placebo-controlled, double-blind study of intravenous calcium and magnesium to prevent oxaliplatin-induced sensory neurotoxicity (N08CB/Alliance).
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 02 December 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Phase III randomized, placebo- ...... eurotoxicity (N08CB/Alliance).
@en
Phase III randomized, placebo- ...... eurotoxicity (N08CB/Alliance).
@nl
type
label
Phase III randomized, placebo- ...... eurotoxicity (N08CB/Alliance).
@en
Phase III randomized, placebo- ...... eurotoxicity (N08CB/Alliance).
@nl
prefLabel
Phase III randomized, placebo- ...... eurotoxicity (N08CB/Alliance).
@en
Phase III randomized, placebo- ...... eurotoxicity (N08CB/Alliance).
@nl
P2093
P2860
P921
P356
P1476
Phase III randomized, placebo- ...... eurotoxicity (N08CB/Alliance).
@en
P2093
Axel Grothey
Charles L Loprinzi
Drew Seisler
Grant C Lewis
Kathleen A Flynn
Louis Fehrenbacher
Pamela Atherton
Rubina Qamar
Shaker R Dakhil
P2860
P304
P356
10.1200/JCO.2013.52.0536
P407
P577
2013-12-02T00:00:00Z